Phase Ib/II Study of Lenvatinib + Pembrolizumab for Patients With Metastatic Renal Cell Carcinoma: Updated Results

June 1-5, 2018; Chicago, Illinois
Lenvatinib plus pembrolizumab associated with an ORR of 63% at 24 weeks and tumor size reduction in 29/30 patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 333 KB
Released: June 7, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Commentary with expert answers to healthcare professional questions on adjuvant therapy for renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Commentary with expert answers to healthcare professional questions on therapy for metastatic renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings